其中，集中竞价减持公司股份不超过4,038,100股，大宗交易减持公司股份不超过6,767,726股。本次 减持计划为深圳纳微股东之一陈荣华根据个人资金需求减持间接持有的公司股份，公司实际控制人、董 事长江必旺博士不减持公司股份。 | 股东名称 | 深圳市纳微科技有限公司 | | --- | --- | | 计划减持数量 | 不超过:10,805,826 股 | | 计划减持比例 | 不超过:2.6759% | | 减持方式及对应减持数 | 集中竞价减持,不超过:4,038,100 股 | | 量 | 大宗交易减持,不超过:6,767,726 股 | | 减持期间 | 2025年9月22日~2025年12月21日 | | 拟减持股份来源 | IP0 前取得 | | 拟减持原因 | 股东之一陈荣华先生个人资金需求 | 截至公告日，公司股东深圳纳微持有公司股份71,406,992股，占公司总股本的17.6831%，其中无限 售条件的流通股71,406,992股。上述股份为公司首次公开发行前取得的股份，并已于2024年6月24日起上 市流通。深圳纳微股东分别为BIWANG JACK JIANG（中文名：江必旺）博士 ...

Summary of Key Points Core Viewpoint - On August 29, Guizhou Moutai announced plans for a significant share buyback, while 13 other listed companies disclosed their intentions to reduce shareholdings [1][2]. Group 1: Guizhou Moutai - The controlling shareholder of Guizhou Moutai intends to increase its stake by purchasing shares worth between 3 billion to 3.3 billion yuan [2]. Group 2: Companies Reducing Holdings - Several companies announced share reductions, including: - Siyi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce its stake by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their stake by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce his stake by up to 0.0615% [2]. - Aorite: Tian Tai Bolong plans to reduce its holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce his stake by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce his holdings by up to 1% [2].

Summary of Key Points Core Viewpoint - On August 29, 2023, Guizhou Moutai announced plans for significant stock buybacks, while 13 other listed companies disclosed their intentions to reduce shareholdings, indicating a mixed sentiment in the market regarding stock ownership adjustments [1][2]. Group 1: Stock Buybacks - Guizhou Moutai's controlling shareholder intends to increase their stake by purchasing between 3 billion to 3.3 billion yuan worth of company shares [2]. Group 2: Stock Reductions - Several companies announced share reductions, including: - Sayi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce holdings by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their holdings by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce holdings by up to 0.0615% [2]. - Aoyue Technology: Tian Tai Bolong plans to reduce holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce holdings by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce holdings by up to 1% [2].

Core Viewpoint - Nanwei Technology (688690.SH) announced that Mr. Chen Ronghua intends to reduce his shareholding in the company through a plan to sell all shares indirectly held by Shenzhen Nanwei [1] Group 1 - Mr. Chen Ronghua has sent a notice regarding his share reduction plan [1] - The reduction involves all shares held indirectly by Shenzhen Nanwei [1]

证券代码：688690 证券简称：纳微科技 公告编号：2025-031 苏州纳微科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 注：以上持股比例差异是由四舍五入造成的，并非数据错误。 2 股东名称 深圳市纳微科技有限公司 股东身份 控股股东、实控人及一致行动人 √是 □否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他： 持股数量 71,406,992股 持股比例 17.6831% 当前持股股份来源 IPO 前取得：71,406,992股 上述减持主体存在一致行动人： 大股东及其一致行动人过去 12 个月内减持股份情况 股东名称 减持数量 （股） 减持比例 减持期间 减持价格区间 （元/股） 前期减持计划 披露日期 深圳市纳微 科技有限公 司 6,690,000 1.6567% 2024/9/26 ～ 2024/12/24 16.3-19.10 2024/8/31 苏州纳研管 理咨询合伙 3,355,5 ...

Group 1 - The core point of the article is that Chen Ronghua plans to reduce his shareholding in Nawi Technology (688690.SH) through a share reduction plan [1] - Chen Ronghua intends to sell a total of up to 10,805,826 shares, which represents 2.6759% of the company's total share capital [1] - The share reduction will occur within three months starting from 15 trading days after the announcement, utilizing both centralized bidding and block trading methods [1] Group 2 - The plan includes a maximum of 4,038,100 shares to be sold through centralized bidding and up to 6,767,726 shares through block trading [1] - The share reduction is based on Chen Ronghua's personal financial needs, while the company's actual controller and chairman, Dr. Jiang Biwang, will not reduce his shareholding [1]

Core Viewpoint - Nanwei Technology (688690.SH) announced that shareholder Chen Ronghua plans to reduce his indirect holdings by up to 10.8058 million shares, accounting for 2.6759% of the company's total share capital, from September 22, 2025, to December 21, 2025. The company's actual controller and chairman, Dr. Jiang Biwang, will not reduce his shareholdings [1] Summary by Category - Shareholder Actions - Chen Ronghua intends to reduce his indirect shareholdings through centralized bidding and block trading [1] - The total number of shares to be reduced is up to 10.8058 million [1] - Company Ownership Structure - The planned reduction represents 2.6759% of the company's total share capital [1] - Dr. Jiang Biwang, the actual controller and chairman, will not participate in any share reduction [1] - Timeline - The reduction period is set from September 22, 2025, to December 21, 2025 [1]

Financial Performance - Company reported a total revenue of 414 million yuan for the first half of 2025, representing a year-on-year increase of 21.74% [1] - Net profit attributable to shareholders reached 63.31 million yuan, up 40.52% year-on-year [1] - Gross margin stood at 72.06%, a slight decrease of 0.5% compared to the previous year, while net margin increased by 23.4% to 15.86% [1] - Total operating expenses were 132 million yuan, accounting for 32.0% of revenue, down 5.96% year-on-year [1] Key Financial Metrics - Earnings per share (EPS) increased by 41.07% to 0.16 yuan [1] - Operating cash flow per share rose significantly by 80.01% to 0.06 yuan [1] - The company's return on invested capital (ROIC) was 4.31% last year, indicating a relatively weak capital return [3] - The company’s historical median ROIC since listing is 10.6%, with the worst year being 2023 at 3.31% [3] Strategic Initiatives - Company emphasizes a customer-centric marketing strategy, focusing on building strategic partnerships with key clients [5] - Revenue from strategic clients in the biopharmaceutical sector accounted for approximately 50% of sales in 2024, showcasing the effectiveness of deepening strategic collaborations [5] - The company aims to enhance customer satisfaction and leverage strategic client relationships to drive revenue growth [5] Fund Holdings - The largest fund holding in the company is from Huatai-PineBridge, with a total of 1.0052 million shares newly entered into the top ten holdings [4] - Other funds that have newly entered the top ten holdings include Bosera Health Growth and Bosera Health Life, indicating growing institutional interest [4]

苏州纳微科技股份有限公司 2025 年度"提质增效重回报"行动方案的半年度评估报告 根据公司了解到的客户应用项目信息统计，本报告期应用于胰岛素、多肽、 抗生素等三类中小分子药物项目的色谱填料产品实现销售收入约 1.02 亿元，较 上年同期增长约 48%。公司具有聚合物反相、离子交换、疏水层析和硅胶反相等 全系列自主创新产品，在包括 GLP-1 在内的多肽类药物应用方向积累形成丰富应 用案例，本报告期在多肽类药物实现色谱填料销售收入约 0.75 亿元，较上年同 期增长约 108%。 2025 年公司继续全面深化战略客户合作关系，加强客户工艺服务能力，在关 键项目上力争赢得订单。上半年新增一家签约战略客户绿叶生命科学集团有限公 为践行"以投资者为本"的上市公司发展理念，推动公司持续提升经营质 量，助力市场信心提振、资本市场稳定和经济高质量发展，苏州纳微科技股份有 限公司（以下简称"公司"）于 2025 年 4 月 25 日发布了《2025 年度"提质增效 重回报"行动方案》。公司根据行动方案内容，积极开展和落实各项工作，现将 公司 2025 年上半年在经营管理、公司治理、募投项目建设、投资者回报等方面 的执行情况 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's core business is showing positive operational trends, with significant growth in overseas market expansion opportunities [1][6] - The company reported a revenue of 414 million yuan for H1 2025, representing a year-on-year growth of 21.74%, and a net profit of 63 million yuan, up 40.52% year-on-year [1][2] Revenue and Profit Analysis - Revenue growth is recovering, with a notable performance in profits. Excluding the impact of Fuli Instruments in January and February 2025, the revenue growth for H1 2025 is 16.20% year-on-year [2] - The core business of chromatography fillers and media generated revenue of 238 million yuan, a growth of approximately 20% year-on-year [2][3] - The overall gross margin for H1 2025 was 72.06%, a slight decrease of 0.36 percentage points year-on-year, primarily due to the consolidation of Fuli Instruments [2] Business Segment Performance - The chromatography fillers and media segment saw a revenue of 238 million yuan, with significant contributions from small molecule drugs, particularly driven by the demand for GLP-1 and other peptide drugs, which achieved a revenue of 75 million yuan, growing 108% year-on-year [3][5] - The company has established strong strategic partnerships, with sales from signed biopharmaceutical clients reaching 108 million yuan, accounting for about 45% of the chromatography fillers business revenue [5] International Market Expansion - The company is actively expanding its international market presence, with international revenue for H1 2025 reaching 44 million yuan, a year-on-year increase of approximately 136% [6] - The company is well-positioned to benefit from the increasing number of domestic innovative drug companies expanding overseas, potentially entering the supply chains of large multinational corporations [6] Financial Forecast - The company is projected to achieve revenues of 984 million yuan, 1.212 billion yuan, and 1.496 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 142 million yuan, 214 million yuan, and 284 million yuan [8] - The estimated EPS (diluted) for the years 2025, 2026, and 2027 are 0.35 yuan, 0.53 yuan, and 0.70 yuan, respectively, with corresponding P/E ratios of 82.27, 54.62, and 41.20 [8]